No Data
No Data
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron
Pfizer (PFE) said Thursday it will conduct dose optimization studies of danuglipron in the second half of the year after selecting a once-daily, modified-release formulation of the drug candidate
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $29
Morgan Stanley analyst Terence Flynn maintains $Pfizer(PFE.US)$ with a hold rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 64.8% and a
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
Jefferies analyst Akash Tewari maintains $Pfizer(PFE.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 58.5% and a total
Pfizer Options Spot-On: On July 11th, 206.89K Contracts Were Traded, With 2.84 Million Open Interest
On July 11th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 206.89K options for the day, of which put options accounted for 31.5% of the total transactions, and call
Express News | CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Shares of $Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.
loading...
No Data
Arrayfunction : I personally got out of Pfizer after a few months. I don't see any reason for it to go to the moon any time soon and has been down more than up lately so $2.25 profit per share was enough for me